Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 943-097-3
CAS number: -
The absorption, distribution, metabolism and excretion of FAT 40032/G TE
have been predicted primarily using information derived from closely
related chemical structures to FAT 40032/G TE. The derivatives of FAT
40032/G TE are highly water soluble which suggests absorption of FAT
40032/G TE would occur in the gastro-intestinal tract following oral
gavage administration subsequently entering the circulatory system via
the blood stream. The physico-chemical properties of the test substance
indicate the risk of uptake from inhalation of volatile material to be
unlikely. However, derivatives of FAT 40032/G TE were shown to elicit
irritation to the skin and eyes and to cause skin sensitization hence
limited absorption may also occur via damaged skin which suggests FAT
40032/G may have the capacity to bind to carrier proteins. Single and
repeated dose toxicological studies conducted on derivatives of FAT
40032/G TE indicated low general systemic toxicity. However, selective
toxicity namely for parental reproductive toxicity (NOAEL: 300 mg/kg
bw/day) and offspring developmental toxicity (NOAEL 100 mg/kg bw/day)
were identified in the reproductive and developmental rodent screening
study conducted with a derivative of FAT 40032/G TE. The data derived
from the repeated dose toxicity and reproductive screening studies also
identified test item or metabolite staining of the urine, faeces and
internal organs. Such findings would corroborate that systemic
distribution of FAT 40032/G TE would be via the serum. However, the low
log octanol/water partition coefficient and water solubility indicate
FAT 40032/G TE to be largely hydrophilic and hence unlikely to
accumulate in body fat.
There was no evidence to indicate test item influenced hepatic
metabolism and available results also verified that FAT 40032/G TE is
unlikely to be mutagenic. Based on the available facts excretion of FAT
40032/G TE and any of its predicted metabolites is expected to be from
the urine and faeces with the latter from non-absorbed test material. To
conclude, the results from the studies conducted provide evidence that
absorption of FAT 40032/G TE would primarily take place in the
gastrointestinal tract following oral ingestion. Once absorbed, FAT
40032/G TE would in all probability be distributed in the serum. Some
absorption may also potentially occur through the skin barrier although
low fat solubility would suggest that significant binding to body fat is
unlikely. There was no evidence to indicate test item or metabolite
influenced hepatic metabolism and excretion of the test substance and/or
its metabolites would predominantly be via the urine and faeces.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Tato webová stránka používá cookies, aby se vám naše stránky používaly co nejlépe.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again